2024 ECTRIMS study identifies sNfL and sGFAP biomarkers predicting MS disability progression.
A study presented at ECTRIMS 2024 identified biomarkers that can predict worsening disability in multiple sclerosis (MS). Elevated serum neurofilament light chain (sNfL) levels at disease onset were linked to a 45% increased risk of relapse-associated worsening (RAW) and a 43% risk of progression independent of relapse activity (PIRA). Additionally, high serum glial fibrillary acidic protein (sGFAP) levels correlated with PIRA in patients with low sNfL. These findings may facilitate personalized treatment strategies for MS patients.
September 19, 2024
8 Articles